Sanofi’s Amlitelimab Demonstrates Promise in Atopic Dermatitis
Following the positive findings from the COAST 1 trial (NCT06130566) reported in September 2025, two additional global Phase 3 studies, SHORE (NCT06224348) and COAST 2 (NCT06181435), have further strengthened the clinical evidence supporting amlitelimab in patients aged 12 years and older with moderate-to-severe atopic dermatitis. Amlitelimab is a fully human monoclonal antibody that selectively inhibits OX40-ligand (OX40L) without depleting T cells. Across both studies, amlitelimab demonstrated favorable tolerability, with a safety profile consistent with previously reported results.
“These findings...
